Whittier Trust Co. of Nevada Inc. Sells 1,492 Shares of Stryker Corporation (NYSE:SYK)

Whittier Trust Co. of Nevada Inc. lessened its position in Stryker Corporation (NYSE:SYK - Free Report) by 19.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,332 shares of the medical technology company's stock after selling 1,492 shares during the period. Whittier Trust Co. of Nevada Inc.'s holdings in Stryker were worth $2,357,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Elefante Mark B acquired a new stake in Stryker during the 4th quarter valued at approximately $337,000. Mogy Joel R Investment Counsel Inc. increased its position in shares of Stryker by 3.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock worth $36,561,000 after buying an additional 3,218 shares during the period. Ferguson Wellman Capital Management Inc. raised its stake in Stryker by 1.9% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock worth $65,096,000 after buying an additional 3,341 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in Stryker during the first quarter valued at $1,840,000. Finally, Mar Vista Investment Partners LLC boosted its position in Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock valued at $33,572,000 after acquiring an additional 8,353 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 0.4%

Shares of Stryker stock traded down $1.50 on Thursday, hitting $389.38. The company had a trading volume of 537,594 shares, compared to its average volume of 1,350,307. Stryker Corporation has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. The stock has a 50 day moving average of $385.38 and a 200-day moving average of $377.55. The stock has a market capitalization of $148.62 billion, a price-to-earnings ratio of 52.53, a P/E/G ratio of 2.95 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. Stryker's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.50 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's payout ratio is 45.41%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent analyst reports. Truist Financial boosted their price objective on Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research note on Monday, May 5th. Wall Street Zen cut Stryker from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Sanford C. Bernstein set a $450.00 target price on shares of Stryker in a research report on Monday, May 5th. Finally, Roth Mkm increased their target price on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average price target of $428.55.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director directly owned 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 5.90% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.